Devising an optimal Global (G7) Pricing and Reimbursement strategy for an innovative CAR T therapy.

Eradigm were tasked with understanding how the client could be optimally positioned to launch CAR T assets across major markets.

Whist considering the progress and challenges of competitor Pricing & Reimbursement activities alongside the evolving Market Access & regulatory market dynamics, Eradigm sought to determine how competitor P&R strategies and local CAR T MA dynamics may evolve in-line with our clients launch timelines for their assets.

Through implementation of innovative methodology and timely outputs, this long-term partnership has enabled the client to adapt their launch strategy accordingly in real time.